NXL vs. ICAD, NSPR, MBOT, FONR, SRTS, MLSS, GUTS, INO, ZYXI, and CTSO
Should you be buying Nexalin Technology stock or one of its competitors? The main competitors of Nexalin Technology include iCAD (ICAD), InspireMD (NSPR), Microbot Medical (MBOT), FONAR (FONR), Sensus Healthcare (SRTS), Milestone Scientific (MLSS), Fractyl Health (GUTS), Inovio Pharmaceuticals (INO), Zynex (ZYXI), and Cytosorbents (CTSO). These companies are all part of the "medical equipment" industry.
Nexalin Technology vs.
iCAD (NASDAQ:ICAD) and Nexalin Technology (NASDAQ:NXL) are both small-cap computer and technology companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, community ranking, risk, analyst recommendations, earnings and institutional ownership.
In the previous week, iCAD had 4 more articles in the media than Nexalin Technology. MarketBeat recorded 7 mentions for iCAD and 3 mentions for Nexalin Technology. Nexalin Technology's average media sentiment score of 0.71 beat iCAD's score of 0.60 indicating that Nexalin Technology is being referred to more favorably in the news media.
iCAD has a net margin of -17.81% compared to Nexalin Technology's net margin of -3,407.98%. iCAD's return on equity of -15.65% beat Nexalin Technology's return on equity.
iCAD received 226 more outperform votes than Nexalin Technology when rated by MarketBeat users. However, 66.67% of users gave Nexalin Technology an outperform vote while only 60.32% of users gave iCAD an outperform vote.
Nexalin Technology has lower revenue, but higher earnings than iCAD. iCAD is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.
Nexalin Technology has a consensus target price of $5.00, suggesting a potential upside of 174.73%. Given Nexalin Technology's stronger consensus rating and higher probable upside, analysts plainly believe Nexalin Technology is more favorable than iCAD.
24.6% of iCAD shares are owned by institutional investors. Comparatively, 0.6% of Nexalin Technology shares are owned by institutional investors. 10.3% of iCAD shares are owned by insiders. Comparatively, 24.0% of Nexalin Technology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
iCAD has a beta of 1.78, indicating that its stock price is 78% more volatile than the S&P 500. Comparatively, Nexalin Technology has a beta of 4.6, indicating that its stock price is 360% more volatile than the S&P 500.
Summary
Nexalin Technology beats iCAD on 10 of the 18 factors compared between the two stocks.
Get Nexalin Technology News Delivered to You Automatically
Sign up to receive the latest news and ratings for NXL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nexalin Technology Competitors List
Related Companies and Tools
This page (NASDAQ:NXL) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy NXL Stock Free NXL Stock Alerts